Bhavisha Sanadhya's Colleagues at Hematology Cancer Consortium
Bhavisha Sanadhya's Contact Details
Hematology Cancer Consortium
Bhavisha Sanadhya's Company Details
There is an increasingly felt need to establish good cooperative group data in hematological malignancies in India. This is required for us to move forward in developing evidence based and locally relevant treatment protocols and guidelines, rather than just modifying international one's. In the long run this will also evolve into a forum to discuss recent advances and their relevance in our region and also to develop cooperative prospective collaborative trials.The primary goal is to aggregate data that will, in turn, facilitate changes in a scientifically rational way based on the available data. In the long run, it is anticipated that HCC will run investigator-initiated prospective collaborative clinical trials addressing regionally relevant questions and evaluating cost-effective treatment strategies. Studies will include all aspects of hematological cancers including but not limited to basic science, diagnostic tests, monitoring, therapeutic interventions, costs, and long term effects. The studies and questions will be driven by participating members of HCC.The major participants will be physicians dealing with hematological cancers from participating centers. However, nurses, allied health care providers, basic scientists from any organization, long term cancer survivors, members of the pharmaceutical industry, well-wishers, and anyone with an interest in the broad vision of improving medical care and access for patients with hematological cancers are welcome to be a member.Currently, HCC has 15 leading cancer centers as institutional partners across the country; we look forward to expanding the HCC network in the near future to include any institution that is committed to the vision of HCC. The strength of any organization is only as dependent on the enthusiasm of its members and we invite each of you to be active participants in this ambitious venture.